Prevention programmes of progressive renal disease in developing nations

Nephrology

Volumn 11, Issue 4, 2006, Pages 321-328

  Codreanu, Igor ^a,b   Perico, Norberto ^a   Sharma, Sanjib K ^a,c   Schieppati, Arrigo ^a   Remuzzi, Giuseppe ^a,d  

^a OSPEDALI RIUNITI   (Italy)

^b Republican Clinical Hospital   (Moldova)

^c B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cardiovascular diseases; Emerging countries; Prevention; Renal diseases

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; DYSLIPIDEMIA; EARLY DIAGNOSIS; EPIDEMIC; ETHNIC GROUP; FETAL MALNUTRITION; HEALTH CARE COST; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH SURVEY; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; MASS SCREENING; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; SMOKING;

DEVELOPING COUNTRIES; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; PROGRAM DEVELOPMENT;

EID: 33746167730     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00587.x     Document Type: Review

References (62)

1. Srinath Reddy K, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97: 596-601.
2. WHO. The World Health Report 2002. Geneva: World Health Organization, 2002.
3. WHO. The World Health Report 2003-Shaping the Future. Geneva: World Health Organization, 2003.
4. Murray CJL, Lopez AD. The Global Burden of Disease. Boston, MA: Harvard School of Public Health, 1996.
5. Leeder S, Raymond S, Greenberg H et al. A Race Against Time: The Challenge of Cardiovascular Disease in Developing Economies. Columbia Universit, New York. 2004.
6. Bumgarner R. China: non-communicable disease issues and options revisited. Soc. Prev. Med. 2004; 38: 202-10.
7. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br. Med. Bull. 1996; 52: 12-21.
8. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int. 2003; 64 (Suppl. 87): S24-S31.
9. Fogarty International Center. Global Burden of Disease for the Year 2001 By World Bank Region for Use in Disease Control. Priorities in Developing Countries, 2nd edn. 2004. Available at: http://www.fic.nih.gov/dcpp/gbd.html (accessed September 2005).
10. Barsoum RS. End-stage renal disease in the developing world. Artif. Organs 2002; 26: 737-46.
11. Remuzzi G, Weening J. Albuminuria as early test for vascular disease. Lancet 2005; 365: 556-7.
12. Xue J, Ma J, Louis T, Collins A. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J. Am. Soc. Nephrol. 2001; 12: 2753-8.
13. Lysaght M. Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. Nephrol. 2002; 13: S37-S40.
14. Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. J. Am. Med. Assoc. 2000; 284: 2622-4.
15. Disney A. Some trends in chronic renal replacement therapy in Australia and New Zealand. Nephrol. Dial. Transplant. 1997; 13: 854-9. 1998.
16. Canadian Institute for Health Information. Dialysis and renal transplantation, Canadian Organ Replacement Register, Canadian Institute for Health Information, Report V. Ottawa, Ontario. 2001.
17. Zatz R, Romao JE, Noronha IL. Nephrology in Latin America, with special emphasis on Brazil. Kidney Int. 2003; 63 (Suppl. 83): S131-S134.
18. Naicker S. End-stage renal disease in sub-Saharan and South Africa. Kidney Int. 2003; 63 (Suppl. 83): S119-S122.
19. Kher V. End-stage renal disease in developing countries. Kidney Int. 2002; 62: 350-62.
20. Li L. End stage renal disease in China. Kidney Int. 1996; 49: 287-301.
21. Rutkowski B, Ciocalteu A, Djukanovic L et al. Treatment of end-stage renal disease in central and eastern europe: overview of current status and future needs. Artif. Organs 1998; 22: 187-91.
22. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003; 41: 1-12.
23. Hoy WE, Rees M, Kile E et al. A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. Kidney Int. 1999; 56: 1072-7.
24. Reyes L, Manalich R. Long-term consequences of low birth weight. Kidney Int. 2005; 68 (Suppl. 97): S107-S111.
25. Leroy B, Josset P, Morgan G et al. Intrauterine growth retardation (IUGR) and nephron deficit: preliminary study in man. Pediatr. Nephrol. 1992; 6: C21.
26. Hinchliffe SA, Lynch MR, Sargent PH et al. The effect of intrauterine growth retardation on the development of renal nephrons. BJOG 1992; 99: 296-301.
27. Manalich R, Reyes L, Herrera M et al. Relationship between weight at birth and number and size of renal glomeruli in humans: a histomorphometric study. Kidney Int. 2000; 58: 770-73.
28. Caballero B. A nutrition paradox-underweight and obesity in developing countries. N. Engl. J. Med. 2005; 352: 1514-16.
29. Rose G. Sick individuals and sick populations. Int. J. Epidemiol. 1985; 14: 000-000.
30. Harwell TS, Nelson RG, Little RR et al. Testing for microalbuminuria in: barriers to implementing current guidelines. Am. J. Kidney Dis. 2002; 42: 245-9. 2003.
31. Carel RS, Silverberg DS, Kaminsky R, Aviram A. Routine urinalysis (dipstick) findings in mass screening of healthy adults. Clin. Chem. 1987; 33: 2106-8.
32. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-9.
33. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann. Intern. Med. 1999; 131: 660-67.
34. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995; 311: 1595-9.
35. Palmer AJ, Weiss C, Sendi PP et al. The cost-effectiveness of different management strategies for type I diabetes. Diabetologia 2000; 43: 13-26.
36. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US Adults. A cost-effectiveness analysis. JAMA 2003; 290: 3101-14.
37. Ruggenenti P, Pagano E, Tammuzzo L et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int. 2001; 59: 286-94.
38. Thomas MC, Cooper ME, Shahinfar S, Brenner BM. Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. Kidney Int. 2003; 63: 1577-9.
39. Palmer AJ, Annemans L, Roze S et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in UK setting. J. Hum. Hypertens. 2004; 18: 733-8.
40. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
41. Asselbergs FW, Diercks GF, Hillege HL et al. Prevention of renal and vasular end stage disease intervention trial (PREVEND IT) investigators. Effects of fosinopril and pravastin on cardiovascular events in microalbuminuric subjects. Circulation 2004; 110: 2809-16.
42. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J. Am. Soc. Nephrol. 2003; 14 (Suppl. 2): S131-S138.
43. Ramirez SPB, Hsu SI-H, McClellan W. Taking a public health approach to the prevention of end-stage renal disease: the NKF Singapore programme. Kidney Int. 2003; 63 (Suppl. 83): S61-S65.
44. Iseki K. The Okinawa Screening Programme. J. Am. Soc. Nephrol. 2003; 7 (Suppl. 2): S127-S130.
45. Mani MK. Prevention of chronic renal failure at the community level. Kidney Int. 2003; 63 (Suppl. 83): S86-S89.
46. Mani MK. Experience with a programme for prevention of chronic renal failure in India. Kidney Int. 2005; 67 (Suppl. 94): S75-S78.
47. Plata R, Silva C, Yahuita J, Perez L, Schieppati A, Remuzzi G. The first clinical epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in developing countries. Nephrol. Dial. Transplant. 1998; 13: 3034-6.
48. Plata R, Cornejo A, Arratia C et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002; 359: 663-6.
49. Mohammed DES. Gauteng Health Department Report on Hypertension and Diabetes control at Soweto Clinics, in Johannesburg. Johannesburg, Gauteng Health Department, 2000.
50. Katz IJ, Butler O, Hopley M. An Early Evaluation of the Primary Prevention Programme (PPP), A Kidney Disease Renoprotection Programme (KDRP), in South African Renal Society Biannual Congress. Bloemfontein: Department of Renal Medicine, 2002.
51. Herrera-Valdes R, Almaguer-Lopez M. Strategies for national health care systems and centers in the emerging world: central America and the Caribbean - the case of Cuba. Kidney Int. 2005; 68 (Suppl. 98): S66-S68.
52. Sharma SK, Dhakal SS, Shrestha NR et al. Chronic kidney disease and risk factors for CKD at community in Nepal-a pilot study. Nephrology 2005; 10 (Suppl.): A147.
53. Codreanu I, Tanase A, Sali V et al. Initial results of a programme for detection and management of chronic kidney disease, hypertension, diabetes and cardiovascular disease in the Republic of Moldova. Nephrology 2005; 10 (Suppl.): A139.
54. Palmer AJ, Annemans L, Roze S et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27: 1897-903.
55. Hooi LS, Wong HS, Morad Z. Prevention of renal failure: the Malaysian experience. Kidney Int. 2005; 67 (Suppl. 94): S70-S74.
56. U.S. Renal Data System. USRDS 2003 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, USRDS, 2003.
57. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479-87.
58. Scavini M, Shah VO, Stidley CA et al. Kidney disease among the Zuni Indians: the Zuni Kidney Project. Kidney Int. 2005; 68 (Suppl. 97): S126-31.
59. Dyck RF. Tracking ancient pathways to a modern epidemic: diabetic end-stage renal disease in Saskatchewan aboriginal people. Kidney Int. 2005; 68 (Suppl. 97): S53-7.
60. McDonald SP, Maguire GP, Hoy WE. Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. Nephrol. Dial. Transplant. 2003; 18: 1555-61.
61. Henry D, Lexchin J. The pharmaceutical industry as a medicine provider. Lancet 2002; 369: 1590-95.
62. Schieppati A, Remuzzi G. The future of renoprotection: frustration and promises. Kidney Int. 2003; 64: 1947-55.